---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-24-000011"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T07:28:22.237713+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Biohaven reports Q4 net loss $144.8M, cash $385.5M; key pipeline data milestones in 2024

## Summary
- Q4 2023 net loss $144.8M ($1.81/sh); non-GAAP adj net loss $128.9M ($1.61/sh).
- Cash, equivalents & securities $385.5M as of Dec 31, 2023 (incl. $3.7M restricted).
- Public offering closed Oct 2023: 11.76M shares at $22, net proceeds ~$242.4M.
- BHV-1300 Phase 1 IgG lowering data expected late Q1/early Q2 2024.
- Troriluzole Phase 3 OCD interim analysis topline results expected Q2 2024; taldefgrobep SMA data H2 2024.

## SEC filing metadata
- accession: 0001935979-24-000011
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000011/0001935979-24-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000011/bhvn-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-24-000011
- JSON: https://secwatch.observer/filing/0001935979-24-000011.json
- Plain text: https://secwatch.observer/filing/0001935979-24-000011.txt

## Key facts
- Earnings Releases
  Biohaven Ltd. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a review of recent accomplishments and anticipated upcoming developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000011/0001935979-24-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.